MIR30A

Summary

MIR30A (microRNA 30a, HGNC:31624) is a microRNA gene on chromosome 6q13.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The encoded miRNA is one of five members of the miR-30 family of highly conserved miRNAs and participates in many cellular processes. It has additionally been implicated in the development of several types of cancer. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407029 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31624
Approved symbol	MIR30A
Name	microRNA 30a
Location	6q13
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-30a
Ensembl gene	ENSG00000207827
Ensembl biotype	miRNA
OMIM	612329
Entrez	407029
RNAcentral	URS000043D261 — miRNA, 71 nt, 23 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385092

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385092 — 1 exons

Exon	Start	End
ENSE00001500098	71403551	71403621

Expression profiles

Bgee: expression breadth broad, 37 present calls, max score 89.53.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4481 / max 148.7481, expressed in 85 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
74330	0.4481	85

Top tissues by expression

37 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
renal glomerulus	UBERON:0000074	89.53	gold quality
lung	UBERON:0002048	86.36	gold quality
blood	UBERON:0000178	81.62	gold quality
heart	UBERON:0000948	77.90	gold quality
kidney	UBERON:0002113	76.57	gold quality
skin of leg	UBERON:0001511	73.11	gold quality
prostate gland	UBERON:0002367	71.39	gold quality
monocyte	CL:0000576	71.14	gold quality
endometrium	UBERON:0001295	71.08	gold quality
uterus	UBERON:0000995	71.06	gold quality
stomach	UBERON:0000945	70.92	gold quality
pituitary gland	UBERON:0000007	69.54	gold quality
omental fat pad	UBERON:0010414	68.81	gold quality
muscle layer of sigmoid colon	UBERON:0035805	68.62	gold quality
left coronary artery	UBERON:0001626	66.76	gold quality
lower esophagus muscularis layer	UBERON:0035833	66.33	gold quality
midbrain	UBERON:0001891	65.20	gold quality
body of stomach	UBERON:0001161	64.89	gold quality
adult mammalian kidney	UBERON:0000082	64.58	gold quality
Ammon’s horn	UBERON:0001954	63.86	gold quality
subcutaneous adipose tissue	UBERON:0002190	63.86	gold quality
epididymis	UBERON:0001301	63.77	gold quality
ovary	UBERON:0000992	63.44	gold quality
right frontal lobe	UBERON:0002810	62.76	gold quality
frontal lobe	UBERON:0016525	62.76	gold quality
spleen	UBERON:0002106	62.19	gold quality
intestine	UBERON:0000160	61.94	gold quality
thyroid gland	UBERON:0002046	60.47	gold quality
transverse colon	UBERON:0001157	60.12	gold quality
left lobe of thyroid gland	UBERON:0001120	60.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.05

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• MiR-30 family are involved in the BDNF gene expression during late maturation and aging of human prefrontal cortex. (PMID:18632683)
• miRNA expression pattern may serve as biomarker of human renal allograft status (PMID:19289845)
• Beclin 1 is a potential target for miRNA miR-30a. (PMID:19535919)
• 2.9 angstrom structure of the pre-miRNA nuclear export machinery formed by pre-miRNA complexed with Exp-5 and RanGTP; RNA recognition by Exp-5:RanGTP does not depend on RNA sequence, implying that Exp-5:RanGTP can recognize a variety of pre-miRNAs (PMID:19965479)
• Data show that overexpression of miR-30a or -191 does not lead to an alteration in cell cycle, proliferation, xenograft formation, and chemosensitivity of A549 and BEAS-2B cell lines. (PMID:20169152)
• Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. (PMID:20498642)
• miR-30 family microRNAs form a part of the regulatory signaling events involved in cellular response of pancreatic epithelial cells during mesenchymal transition. (PMID:21099261)
• miR-29 and miR-30 regulate B-Myb expression by binding to its 3’UTR; these microRNAs play an important role in Rb-driven cellular senescence (PMID:21187425)
• These results suggest that miR-30a targets Snai1, inhibits invasion and metastasis, and is downregulated in NSCLC. (PMID:21633953)
• MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. (PMID:22157765)
• data identified miR-30a-5p as a tumor-suppressing miRNA in colon cancer cells exerting its function via modulation of DTL expression, which is frequently overexpressed in colorectal cancer (PMID:22287560)
• trastuzumab modulates the expression of a subset of microRNAs, including miR-26a and miR-30b (PMID:22384020)
• miR-30a downmodulates vimentin expression might provide a therapeutic target for the treatment of breast cancer. (PMID:22476851)
• we show that miR-30a-5p provides an essential link between EWS-FLI1 and CD99, two major biomarkers in Ewing sarcoma (PMID:22986530)
• circulating miR-30a was higher in acute myocardial infarction patients than in controls at 4, 8, and 12 hours post-AMI. plasma concentration of miR-30a could be a potential indicator for AMI. (PMID:23236408)
• miR-30a acts as a tumor suppressor by downregulating ABL1 and BCR-ABL1 expression. (PMID:23287430)
• plasma miRNA-30a is decreased in patients with breast cancer (PMID:23389917)
• These results reveal that elevated expression of miR-30a is responsible for the reduction in levels of Lyn in B cells from patients with systemic lupus erythematosus, suggesting that miR-30a plays an important role in B cell hyperactivity. (PMID:23450709)
• Overexpression of miR-30a suppressed CRC cell migration and invasion in vitro and liver metastasis in vivo. (PMID:23486085)
• Observations indicate stage-specific roles of OstemiR especially miR-541 and the miR-30 family on novel targets in osteogenesis. (PMID:23533592)
• The expression of miR-30a-5p in malignant glioma cell lines and glioma samples were examined by qRT-PCR and in situ hybridization. Show miR-30a-5p is overexpressed in glioma cell lines and glioma samples as compared to normal brain tissues. (PMID:23606081)
• miR-210 and miR-30a were elevated in chronic heart failure patients and fetal blood. (PMID:23660476)
• BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. (PMID:23758992)
• Our data suggest that miR-30a stimulates arteriolar branching by downregulating endothelial Dll4 expression, thereby controlling endothelial tip cell behavior. (PMID:23817492)
• miR-30a was down-regulated in clear cell renal cell carcinoma and further decreased in clear cell renal cell carcinoma with hematogenous metastasis. Mechanistically, down-regulation of miR-30a increased microvessel density by targeting DLL4. Clinically, low-level miR-30a indicated a higher probability of developing metastasis and shorter metastasis-free survival. (PMID:23826258)
• miR-30a negatively regulates Snai1-mediated EMT during peritoneal fibrosis in vitro and in vivo. (PMID:23831330)
• Loss of MicroRNA-30a is associated with breast tumor growth and metastasis. (PMID:23851509)
• examined the expression of the miR-30 family in the podocytes of patients with focal segmental glomerulosclerosis and found that all members are downregulated (PMID:24029422)
• MYBL2 overexpression was associated with lower expression of miR-30a (P=0.024), miR-30b (P=0.021) and miR-30c (P=0.009). (PMID:24199710)
• overexpression and depletion of miR-30a-5p in the paclitaxel-resistant cells decreased and increased paclitaxel sensitivity, respectively. (PMID:24220856)
• Circulating miR-30a levels are markedly down-regulated in all patients with ischemic stroke until 24 weeks. (PMID:24237608)
• Decreased MIRN30A expression is associated with metastasis in clear cell renal cell carcinoma. (PMID:24242678)
• miR-30a-3p is downregulated in hepatocellular carcinoma and inhibits tumor proliferation, invasiveness, and metastasis. (PMID:24290372)
• RUNX3 suppressed gastric cancer cell invasion and vimentin expression by activating miR-30a. (PMID:24447545)
• MIR30A represses Eya2 expression by binding to the 3’-untranslated region of Eya2.The MIR30A/EYA2 axis regulates breast cancer cell proliferation and migration. (PMID:24508260)
• Downregulation of the tumor suppressor microRNA miR-30-5p is a frequent pathogenetic event in multiple myeloma. (PMID:24599134)
• Results found that miR-30a* and miR-30e* were the top 2 significantly different miRNAs between type I and type II ovarian papillary serous carcinoma patients, and both were remarkably downregulated in the latter type. (PMID:24676806)
• Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of miR-100, miR-222, and miR30a. (PMID:24740415)
• In monocytes of sepsis, the expression of MD-2 was inhibited via miR-30a. (PMID:24858600)
• significant downregulation of miR-30a in hepatocellular carcinoma (HCC) tissues and cell lines compared with non-tumor counterparts (PMID:24954667)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir30a	ENSMUSG00000065405
rattus_norvegicus	Mir30a	ENSRNOG00000035646

Paralogs (5): MIR30E (ENSG00000198974), MIR30C2 (ENSG00000199094), MIR30D (ENSG00000199153), MIR30B (ENSG00000207582), MIR30C1 (ENSG00000207962)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.